Publisert 29.08.2016

Succesfull placement of share issue August 2016

Regenics announces the succesfull private placement of new shares.

According to resolutions by the Board of Directors on July 11th 2016 a limited private placement to existing shareholders and management was subscribed on August 29th 2016 securing a net equity of 1.720 mill NOK to allow further co-funding of granted public R&D grants from the Eurostars and BIA research programmes.

For further details and info contact: 

Chairman Board od Directors Tore H. Rasmussen at or mobile +47 95892548 



Regenics AS has developed a number of assays and techniques to study effects of various substances on skin cells both in vitroin vivo and in the clinic. Our focus is to develop products and techniques for therapeutic skin applications and to improve skin appearance.